Cargando…
Statins and endocrine resistance in breast cancer
Most breast cancers are hormone-receptor positive (HR(+)). However, more women eventually die from HR(+) breast cancer than from either HER2(+) or triple negative breast cancer. Endocrine therapies continue to be the mainstay of treatment. In 40% of these cases, recurrences in early-stage disease an...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019265/ https://www.ncbi.nlm.nih.gov/pubmed/35582035 http://dx.doi.org/10.20517/cdr.2020.112 |